PAVmed Inc PAVM Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.57 up $0.02, 1.34% at close Nov 6
Last close · Previous close $1.55
- Market cap
- $11.42MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.57down $1.10, 41.28%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.55Nov 5
- Volume10.20KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume12.04KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.53 to $28.44; now $1.57
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PAVM trailed the S&P 500 in all 7 periods.
| Period | PAVM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PAVM: down 41.3% S&P 500: down 5.6% | PAVM trailed the S&P 500 by 35.7 percentage points Trailed |
| 3M | PAVM: down 68.2% S&P 500: down 4.1% | PAVM trailed the S&P 500 by 64.1 percentage points Trailed |
| YTD | PAVM: down 76.3% S&P 500: up 8.7% | PAVM trailed the S&P 500 by 85.0 percentage points Trailed |
| 1Y | PAVM: down 83.4% S&P 500: up 10.9% | PAVM trailed the S&P 500 by 94.3 percentage points Trailed |
| Long term | ||
| 3Y | PAVM: down 98.7% S&P 500: up 75.0% −76.5% vs +20.5% a year | PAVM trailed the S&P 500 by 173.7 percentage points Trailed |
| 5Y | PAVM: down 99.9% S&P 500: up 67.8% −77.1% vs +10.9% a year | PAVM trailed the S&P 500 by 167.7 percentage points Trailed |
| 10Y | PAVM: down 100.0% S&P 500: up 313.1% −55.1% vs +15.2% a year | PAVM trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in PAVM 10 years ago (Nov 4, 2016) would be worth about $3 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
PAVM trailed the S&P 500 in all 7 periods.
| Period | PAVM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PAVM: down 41.3% S&P 500: down 5.6% | PAVM trailed the S&P 500 by 35.7 percentage points Trailed |
| 3M | PAVM: down 68.2% S&P 500: down 4.3% | PAVM trailed the S&P 500 by 63.9 percentage points Trailed |
| YTD | PAVM: down 76.3% S&P 500: up 7.8% | PAVM trailed the S&P 500 by 84.1 percentage points Trailed |
| 1Y | PAVM: down 83.4% S&P 500: up 9.7% | PAVM trailed the S&P 500 by 93.1 percentage points Trailed |
| Long term | ||
| 3Y | PAVM: down 98.7% S&P 500: up 68.8% −76.5% vs +19.1% a year | PAVM trailed the S&P 500 by 167.5 percentage points Trailed |
| 5Y | PAVM: down 99.9% S&P 500: up 56.9% −77.1% vs +9.4% a year | PAVM trailed the S&P 500 by 156.8 percentage points Trailed |
| 10Y | PAVM: down 100.0% S&P 500: up 252.6% −55.1% vs +13.4% a year | PAVM trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in PAVM 10 years ago (Nov 4, 2016) would be worth about $3 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$6,858.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jul 28, 2016.
Stock splits
2
Latest: 1-for-30 on . Share counts adjust after each split.
Both splits
- 1-for-30
- 1-for-15
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
See the note under the price. Over the past five years PAVM’s P/E ranged from 0.1× to 0.9×, with a median of 0.2×. How to read P/E
Other valuation measures
- 102.0×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −68.12%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $24.71MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PAVM DCF in Excel. Value PAVmed with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $112.00Kdown 89.0%
- Net income
- −$12.09M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $996.00K | $64.40M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $10.00K | $1.43M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $8.00K | $18.97M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $6.00K | −$11.92M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $5.00K | −$5.38M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $52.00K | −$1.26M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $22.00K | −$60.00K | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $33.00K | −$5.38M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $500.00K | −$50.35M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $377.00K | −$88.98M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $2.45M | −$64.18M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $3.00M | $39.79M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $71.00K | $401.00K | Paused See the note under the price. |
Margins
- Gross −220.5%
- Operating −23,842.9%
- Net −10,794.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$7.78MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$7.73MLast 12 months
- Capital spending$52.00KLast 12 months
- −6,948.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.49MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $37.28MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$17.07MAs of Jun 30, 2026
- Net cash$20.21MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.19As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.49As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −34.3%Last 12 months
Over the last 12 months, PAVmed lost money: its net loss was 34.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −29.8%Last 12 months
Over the last 12 months, PAVmed’s net loss was 29.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About PAVmed Inc
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform. Its other subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PAVM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PAVM stock FAQ
What is PAVM stock’s price today?
PAVmed (PAVM) traded at $1.57 at the close on , up $0.02 (1.34%) from the previous close of $1.55. Over the past 52 weeks it has traded between $1.53 and $28.44.
If you invested $1,000 in PAVM 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PAVM on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $1 if invested five years ago and $166 if invested one year ago. Past performance doesn’t predict future returns.
What is PAVmed’s market cap?
PAVmed’s market capitalization is about $11.4 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.57 (how market cap works).
How much revenue does PAVmed make?
PAVmed reported $112.0 thousand of revenue over the four quarters to , down 89.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $33.0 thousand, up 450.0% from a year earlier.
Is PAVmed profitable?
Not over the four quarters to . PAVmed reported a net loss of $12.1 million across those four quarters on $112.0 thousand of revenue.
Does PAVM pay a dividend?
PAVmed hasn’t paid a dividend in the last twelve months.
What is PAVM’s 52-week high and low?
Over the past 52 weeks PAVM has traded as low as $1.53 and as high as $28.44. At $1.57 at the close on , it is 94.5% below that high and 2.7% above the low.
What is PAVM’s all-time high?
PAVM’s highest closing price was $6,858.00 on , adjusted for stock splits. At $1.57 at the close on , it is 100.0% below that record.
Has PAVM stock ever split?
Yes, twice: 1-for-15 on ; 1-for-30 on .
How has PAVM stock performed?
Including dividends and measured to the close on , PAVM has returned −76.3% so far this year and −83.4% over the past year, and −99.9% over five years (−77.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is PAVmed in?
PAVmed is in the Healthcare sector and the Medical Devices industry, and is headquartered in New York, USA.
What exchange does PAVM trade on?
PAVmed trades on the Nasdaq under the ticker symbol PAVM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.